Albumin News and Research

RSS

Newly discovered testosterone effect may act on prostate cancer

A newly-discovered mode of action of testosterone is showing great promise in the fight against prostate cancer, with tests showing a 60% reduction in tumor size in mice.

6 Apr 2006

Tobacco plants being used to produce human albumin

Human serum albumin (HSA) is the intravenous protein most commonly used in the world for therapeutic ends. It is employed to stabilise blood volume and to avoid risk of a heart attack, its administration in operating theatres being almost a daily occurrence.

27 Mar 2006

Simple method to diagnose preeclampsia

Researchers at Yale School of Medicine have found that analyzing proteins in urine is a simple and objective method to diagnose and classify preeclampsia (PE), a complication of pregnancy causing high blood pressure after 20 weeks of gestation.

5 Feb 2006

Kidney disease may be a more important risk factor for heart disease than is cholesterol

Jefferson researchers have found that mice with low levels of the protein hormone adiponectin may also have high levels of a protein called albumin which, in humans, may be a sign of kidney disease.

28 Nov 2005

Research points way to more effective delivery of medicine around the body

New research showing how drugs stick to a key protein in the bloodstream could help to create drugs that are delivered more effectively to organs in the body.

13 Oct 2005

New role for the blood protein serum amyloid P in the body's response to medical materials

Using a technique called proteomics, the researchers identified many of the blood proteins that stick (adsorb) to the surfaces of medical devices. Blood proteins that adsorb to the surfaces of materials unfold and can be recognized by the body, which then mounts a response against the device.

5 Oct 2005

Call for closer examination of a metabolic syndrome

Two major health organizations in Europe and the United States are calling for closer examination of a syndrome that has been widely believed to predict the risk of developing heart disease, questioning whether it has been appropriately defined and whether it is in fact a syndrome at all.

25 Aug 2005

Ruboxistaurin shows favorable effects on kidney damage and function in people with type 2 diabetes and nephropathy

Eli Lilly and Company today announced encouraging results from a one-year pilot study examining the effect of ruboxistaurin mesylate in persons with type 2 diabetes and kidney disease (also known as "diabetic nephropathy").

12 Jun 2005

Link between PKC enzyme and kidney disease in diabetes confirmed

Researchers at Joslin Diabetes Center have investigated PKC-beta - a critical enzyme implicated in the devastating complications of type 1 and type 2 diabetes - for more than two decades.

12 Jun 2005

Link between hyperglycemia (high blood glucose), overexpression of PKC-beta 2 and kidney disease

Scientists at Joslin Diabetes Center have investigated PKC-beta -- a critical enzyme implicated in the devastating complications of type 1 and type 2 diabetes -- for more than two decades.

10 Jun 2005

Why different tissues in the human body vary in their susceptibility to "amyloid" diseases

Researchers at The Scripps Research Institute are reporting the results of a recent study that addresses why different tissues in the human body vary in their susceptibility to "amyloid" diseases, which include Alzheimer's disease and a cluster of ailments called the familial amyloidoses.

7 Apr 2005

New color-coded test for protein folding

Every protein--from albumin to testosterone--is folded into a unique, three-dimensional shape that allows it to function properly. Now Stanford University scientists have developed a simple test that instantly changes color when a protein molecule attached to a gold nanoparticle folds or unfolds.

28 Mar 2005

Nonsurgical microspheres an option for liver cancer patients

A study in February’s Journal of Vascular and Interventional Radiology found that patients undergoing liver cancer treatment with Theraspheres?, radioactive microspheres containing Yittrium-90, can tolerate a 150 Gy single dose or 268 Gy repeated dose without risk of radiation-induced liver disease.

17 Feb 2005

Launch date announced for Abraxane to treat metastatic breast cancer

American Pharmaceutical Partners announced today that February 8, 2005 is the launch date of Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound). Abraxane will be marketed by the national sales force of Abraxis Oncology, APP's proprietary sales and marketing division.

25 Jan 2005

Abraxane, first in a new class of albumin-bound nanotechnology for the treatment of metastatic breast cancer

Abraxane (paclitaxel protein-bound particles for injectable suspension), a next generation taxane, and the first in a new class of albumin-bound nanotechnology, was approved for the treatment of metastatic breast cancer.

9 Jan 2005

FDA approves Abraxane for metastatic breast cancer

American Pharmaceutical Partners, Inc. and American Bioscience, Inc. (ABI) announced that the U.S. Food and Drug Administration (FDA) has approved Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in metastatic breast cancer.

9 Jan 2005

Transplanted bone marrow cells reduce liver fibrosis in mice

Transplanted bone marrow cells can reduce carbon tetrachloride-induced liver fibrosis in mice and significantly improve their survival rates, according to a new study

8 Dec 2004

Israeli developed fruit called pomelit, lowers blood cholesterol

People who eat the Israeli-developed fruit known in Hebrew as pomelit (a cross between a grapefruit and a pomelo) or drink its juice regularly will be able to lower their blood cholesterol and increase their blood antioxidant activity, thus improving their chances of preventing blocked heart arteries and heart attacks, says a researcher at the Hebrew University of Jerusalem.

30 Nov 2004

Sit down rounds improve outcomes for kidney dialysis patients

"Sit-down" medical rounds, during which a health care team meets to review a patient's medical record and discuss short- and long-term needs, are associated with better outcomes for kidney dialysis patients, a Johns Hopkins-directed study has found.

17 Nov 2004

Human Genome Sciences announces agreement with GSK for development of drug to treat diabetes

Human Genome Sciences today announced an agreement with GlaxoSmithKline under which GlaxoSmithKline has acquired exclusive worldwide rights to develop and commercialize Albugon (albumin-glucagon-like peptide-1, GLP-1), a drug currently in late-stage preclinical development by Human Genome Sciences for potential use in the treatment of diabetes.

26 Oct 2004